MedTrace Logo

Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent cGVHD

NCT02918188 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2020-07-21

No results posted yet for this study

Summary

This study suggested that hydrogen has a potential as an effective and safe therapeutic agent on cGVHD.

Conditions

  • Chronic Graft-versus-host Disease

Interventions

DRUG

Hydrogen

Patients will receive hydrogen-rich water orally (500mL three times one day, 0.6mM)

Sponsors & Collaborators

  • Navy General Hospital, Beijing

    lead OTHER

Principal Investigators

  • Liren Qian, M.D. · Navy General Hospital, Beijing

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2026-01-31
Completion
2031-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02918188 on ClinicalTrials.gov